HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety profile of sparfloxacin in the treatment of respiratory tract infections.

Abstract
A total of 2081 adult patients with community-acquired lower respiratory tract infections participated in Phase III clinical trials of sparfloxacin. A total of 1040 patients were randomised to sparfloxacin and 1041 patients received a comparator regimen. Sparfloxacin was administered as a 400 mg loading dose on day 1 followed by 200 mg once daily to patients with community-acquired pneumonia and as a 200 mg loading dose on day 1 followed by 100 mg daily to patients with acute exacerbations of chronic obstructive pulmonary disease. Comparator regimens were amoxycillin/clavulanic acid 500/125 mg tid, amoxycillin 1000 mg tid, a combination of amoxycillin 1000 mg tid plus ofloxacin 200 mg bid or erythromycin 1000 mg bid. The incidence of adverse events, the incidence and severity of antibacterial-related adverse events and the incidence of antibacterial discontinuation due to adverse events were no different among patients treated with sparfloxacin compared with those who received a comparator antibacterial agent. Sparfloxacin appears to be as well tolerated as other oral antibacterial regimens commonly used to treat lower respiratory tract infections.
AuthorsE Rubinstein
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 37 Suppl A Pg. 145-60 (May 1996) ISSN: 0305-7453 [Print] England
PMID8737134 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Anti-Infective Agents
  • Fluoroquinolones
  • Quinolones
  • sparfloxacin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents (adverse effects, therapeutic use)
  • Clinical Trials, Phase III as Topic
  • Community-Acquired Infections (drug therapy)
  • Drug Administration Schedule
  • Female
  • Fluoroquinolones
  • Humans
  • Lung Diseases, Obstructive (drug therapy)
  • Male
  • Middle Aged
  • Pneumonia, Bacterial (drug therapy)
  • Quinolones (adverse effects, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Respiratory Tract Infections (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: